Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.

doi:10.1182/bloodadvances.2024014017

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.

Blood advances - 12 Nov 2024

Othman Jad, Hwang Angela, Brodermann Maximillian, Abdallah Islam, McCloskey Kayleigh, Gallipoli Paolo, Clarke Georgina, Dang Raymond, Vidler Jennifer, Krishnamurthy Pramila, Basheer Faisal, Latif Anne-Louise, Palanicawandar Renuka, Taylor Tom, Khan Asra, Campbell Victoria, Hogan Francesca, Kanellopoulos Alex, Fleming Kathryn, Collins Angela, Dalley Chris, Loke Justin, Marshall Scott, Taussig David, Munisamy Sreetharan, Loizou Eleana, Yassin Heba, Dennis Mike, Zhao Rui, Belsham Edward, Murray Duncan, Fowler Nicole, O'Nions Jenny, Khan Anjum, Sellar Rob, Dillon Richard

Abstract excerpt

ABSTRACT: Gilteritinib is the current standard of care for relapsed or refractory fms related receptor tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia in many countries, however outcomes for patients relapsing after contemporary first-line therapies (intensive chemotherapy with midostaurin, or nonintensive chemotherapy with venetoclax) are uncertain. Moreover, reported data on toxicity and health care...

Topics

Humans
fms-Like Tyrosine Kinase 3
Middle Aged
Leukemia, Myeloid, Acute
Pyrazines
Aniline Compounds
Male

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Female

Aged

Mutation

Adult

Treatment Outcome

Aged, 80 and over

Induction Chemotherapy

Protein Kinase Inhibitors

Recurrence

Drug Resistance, Neoplasm

Source

Open in PubMed Open full text

Identifiers

PMID: 39265176
DOI: 10.1182/bloodadvances.2024014017
PMCID: PMC11541456

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-39265176-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.PMID 39265176Read ↗

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.Semantic proximity Read ↗

Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.Semantic proximity Read ↗

Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.Semantic proximity Read ↗

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.Semantic proximity Read ↗

Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.Semantic proximity Read ↗

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.Semantic proximity Read ↗

Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3 Mutated AML PatientsSemantic proximity Read ↗

Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.Semantic proximity Read ↗

Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.Semantic proximity Read ↗

The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.Semantic proximity Read ↗

FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation.Semantic proximity Read ↗

Outcomes of patients with R/R FLT3mut+ AML treated with maintenance gilteritinib therapy after hematopoietic stem cell transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.